A Long-term, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk Not Adequately Controlled by Their Lipid-Modifying Therapy

Trial Profile

A Long-term, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk Not Adequately Controlled by Their Lipid-Modifying Therapy

Recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Bempedoic acid (Primary)
  • Indications Hypercholesterolaemia
  • Focus Therapeutic Use
  • Acronyms CLEAR Wisdom
  • Sponsors Esperion Therapeutics
  • Most Recent Events

    • 04 May 2017 According to an Esperion Therapeutics media release, the patient enrollment in this study will be completed in the second half of 2017.
    • 20 Mar 2017 According to an Esperion Therapeutics media release, top-line results expected by mid-2018.
    • 20 Mar 2017 According to an Esperion Therapeutics media release, company plans to submit a new drug application (NDA) by 1H 2019 based on the successful completion of the global pivotal Phase 3 program. The US FDA also confirmed that LDL-C lowering program is adequate to support approval of an LDL-C lowering indication for bempedoic acid.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top